- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Renal cell carcinoma
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1468KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 213KB)
Cabozantinib – November 2020
Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
Last updated
5 March 2021